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1  | INTRODUC TION
5- Fluorouracil (5- FU) is a key drug in the treatment of colon and gas-
tric cancers. Various combination therapies have been developed 
and improved survival. However, survival duration remains short, 
and cure with chemotherapy is rarely expected.1-5 To circumvent 
such problems, new therapeutic strategies are needed.
In human cancers, the tumor protein (TP)53 tumor suppressor 
gene is often inactivated by missense mutation, or its function is 
suppressed by enhanced expression of oncogenes such as murine 
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Inactivation of the TP53 tumor suppressor gene is essential during cancer develop-
ment and progression. Mutations of TP53 are often missense and occur in various 
human cancers. In some fraction of wild-type (wt) TP53 tumors, p53 is inactivated by 
upregulated murine double minute homolog 2 (MDM2) and MDM4. We previously 
reported that simultaneous knockdown of MDM4 and MDM2	using	synthetic	DNA-	
modified	siRNAs	revived	p53	activity	and	synergistically	inhibited	in	vitro	cell	growth	
in cancer cells with wt TP53 and high MDM4 expression (wtTP53/highMDM4). In the 
present study, MDM4/MDM2	 double	 knockdown	 with	 the	 siRNAs	 enhanced	
5- fluorouracil (5- FU)- induced p53 activation, arrested the cell cycle at G1 phase, and 
potentiated the antitumor effect of 5- FU in wtTP53/highMDM4 human colon 
(HCT116	and	LoVo)	and	gastric	(SNU-	1	and	NUGC-	4)	cancer	cells.	Exposure	to	5-	FU	
alone	induced	MDM2	as	well	as	p21	and	PUMA	by	p53	activation.	As	p53-	MDM2	
forms a negative feedback loop, enhancement of the antitumor effect of 5- FU by 
MDM4/MDM2 double knockdown could be attributed to blocking of the feedback 
mechanism in addition to direct suppression of these p53 antagonists. Intratumor 
injection of the MDM4/MDM2	siRNAs	suppressed	in	vivo	tumor	growth	and	boosted	
the antitumor effect of 5- FU in an athymic mouse xenograft model using HCT116 
cells. These results suggest that a combination of MDM4/MDM2 knockdown and 
conventional cytotoxic drugs could be a promising treatment strategy for wtTP53/
highMDM4 gastrointestinal cancers.
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double minute 2 (MDM2) and MDM4.6-8 MDM2 and its complex with 
MDM4 destabilizes p53 through binding and ubiquitin- dependent 
protein degradation.9,10 MDM4 can also repress p53 transcriptional 
activity by directly binding to the transactivating domain.11,12
Studies have shown that reactivation of wild-type (wt) TP53 
by inhibiting MDM2- p53 interaction or knockdown of MDM2 and 
MDM4 induces cell cycle arrest and apoptotic cell death, inhibiting 
tumor growth in tumors carrying wtTP53.6,13-19 Thus, MDM2 and 
MDM4 are ideal targets for cancer therapy in such tumors. Various 
kinds of small molecular compounds and peptides inhibiting MDM2 
function have been developed.6,18,20,21	 Among	 them,	 idasanutlin	
has been shown to be an effective treatment in some clinical stud-
ies of patients with malignant lymphomas and acute myeloblastic 
leukemias.22-24
A	previous	study	reported	that	cultured	tumor	cells	with	wtTP53 
can be divided into 2 types: high MDM2 expressers and high 
MDM4 expressers.16 The former expresses a high level of MDM2 
and a very low level of MDM4, whereas the latter expresses a high 
level of MDM4 and an intermediate level of MDM2. Knockdown of 
either MDM4 or MDM2	 alone	 using	 synthetic	 siRNAs	with	DNA-	
substituted seed arms (chiMDM4, chiMDM2) specifically sup-
pressed the growth of high MDM4 expresser cancer cells, whereas 
only MDM2 knockdown but not MDM4 knockdown suppressed that 
of high MDM2 expresser cancer cells. Simultaneous knockdown 
of MDM4 and MDM2 synergistically inhibited the growth of high 
MDM4 expresser cancer cells.
Overexpression or amplification of MDM4 has been found 
in 19%- 49% and 43% of colon and gastric cancers, respectively, 
whereas those of MDM2 have been reported in 17.3% and 32.7%- 
41.8% of colon and gastric cancers, respectively.25-29 Therefore, 
reactivation of wtTP53 by chiMDM4 and chiMDM2 could be used 
for the treatment of these cancers. In the present study, the effects 
of double knockdown of MDM4 and MDM2 using chiMDM4 and 
chiMDM2 on the antitumor activity of 5- FU in colon and gastric can-
cer cells with wtTP53 and high MDM4 (wtTP53/highMDM4) were 
investigated. In vivo antitumor activity of chiMDM4 plus chiMDM2 
(chiMDM4/chiMDM2) and a combination of chiMDM4/chiMDM2 
with 5- FU were also explored.
2  | MATERIAL S AND METHODS
2.1 | Cell culture
Four tumor cell lines with wtTP53 were used: HCT116 colon cancer, 
LoVo	colon	cancer,	SNU-	1	gastric	cancer,	and	NUGC-	4	gastric	can-
cer. The HCT116 cell line was purchased from Horizon Discovery 
(Cambridge,	 UK).	 LoVo	 and	 SNU-	1	 cell	 lines	 were	 purchased	 from	
ATCC	(Rockville,	MD,	USA).	The	NUGC-	4	cell	line	was	obtained	from	
the	Riken	BioResource	Center	Cell	Bank	(Tsukuba,	Japan).	HCT116,	
SNU-	1,	 and	 NUGC-	4	 cells	 were	 cultured	 in	 RPMI-	1640	 medium	
(Sigma-	Aldrich,	 St.	 Louis,	 MO,	 USA)	 supplemented	 with	 10%	 FBS	
(Nichirei	 Biosciences,	 Tokyo,	 Japan).	 LoVo	 cells	 were	 cultured	 in	
Ham's	F-	12	nutrient	mixture	medium	(Sigma-	Aldrich)	with	10%	FBS.	
5- Fluorouracil was purchased from Kyowa Hakko Kirin (Tokyo, Japan). 
Nutlin-	3	was	purchased	from	Calbiochem	(San	Diego,	CA,	USA).
2.2 | Small interfering RNAs and transfection
Sequences	 of	 DNA-	modified	 siRNAs	 used	 in	 this	 study	 were:	
chimera	 Control	 (chiControl,	 chiCtrl)	 sense	 strand,	 5′-	GUAC 
CGCACGUCAttcgtatc-	3′;	chiCtrl	antisense	strand,	5′-	tacgaaUGACGU 
GCGGUACGU-	3′;	 chiMDM2	 sense	 strand,	 5′-	CAGCCAUCAACU 
Uctagtagc-	3′;	 chiMDM2	 antisense	 strand,	 5′-	tactagAAGUUGAUG 
GCUGAG-	3′;	 chiMDM4	 sense	 strand,	 5′-	CCCUCUCUAUGAUatg 
ctaag-	3′;	chiMDM4	antisense	strand,	5′-	tagcatAUCAUAGAGAGGG 
CU-	3′;	 chiCtrl	 (in	 vivo)	 sense	 strand,	 5′-	gtaGUACCGCACGUCAttc 
tc-	3′;	and	chiCtrl	(in	vivo)	antisense	strand,	5′-	gaaUGACGUGCGGUAC 
tacGU-	3′	(capital	letters,	ribonucleotides;	small	letters,	deoxynucle-
otides).	The	control	DNA-	modified	siRNA	was	designed	to	have	the	
least homology to human and mouse genes. For the in vitro experi-
ments,	DNA-	modified	siRNAs	were	synthesized,	cartridge-	purified,	
and	 annealed	 (Sigma-	Aldrich).	 For	 the	 in	 vivo	 experiments,	 DNA-	
modified	 siRNAs	 were	 synthesized,	 annealed,	 and	 purified	 using	
HPLC	 (ST	 Pharm.,	 Seoul,	 Korea).	 The	 siRNA	 transfection	 in	 vitro	
experiment	was	carried	out	using	Lipofectamine	RNAiMAX	reagent	
(Invitrogen,	Carlsbad,	CA,	USA)	as	reported	previously,30 except for 
SNU-	1	cells.	Because	Lipofectamine	RNAiMAX	was	toxic	to	SNU-	1	
cells,	 the	 cells	 were	 exposed	 to	 siRNA-	Lipofectamine	 RNAiMAX	
complex for 4 hours, then centrifuged, resuspended in a complete 
medium,	and	cultivated.	The	siRNA	transfection	in	vivo	experiment	
was	undertaken	using	AteloGene	Local	Use	(Koken,	Tokyo,	Japan).
2.3 | Cell viability
Water- soluble tetrazolium salt (WST- 8) colorimetric assays were car-
ried	out	using	a	CCK-	8	(Dojin	Laboratories,	Kumamoto,	Japan)	accord-
ing	to	the	manufacturer's	protocol.	Because	the	maximum	knockdown	
effects	of	siRNAs	were	usually	observed	2-	3	days	after	transfection,	
cells	were	incubated	for	5	days	after	transfection	with	siRNAs	(4	days	
after treatment with 5- FU), which was longer than the period de-
scribed in the manufacturer's protocol (1- 3 days), then analyzed using 
an	iMark	microplate	reader	(Bio-	Rad,	Hercules,	CA,	USA).	The	absorb-
ance of the plates was read at wavelengths of 450 and 620 nm.
2.4 | Combination index
Quantification of the mixture of chiMDM4/chiMDM2 and 5- FU 
synergy was determined by the Chou- Talalay method for drug com-
bination	 using	 CalcuSyn	 software	 (Biosoft,	 Cambridge,	 UK).31 A	
combination index (CI) <0.9 indicates synergism, 09–1.1 indicates 
additivity, and >1.1 indicates antagonism.
2.5 | Immunoblot analysis
Both	SDS-	PAGE	and	immunoblot	analysis	were	carried	out	as	previously	
described.16	 The	 primary	 and	 secondary	 Abs	 used	 in	 this	 study	 were:	
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mouse	mAb	against	MDM2	(2A10)	(Abcam,	Cambridge,	UK);	goat	poly-
clonal	Ab	 against	MDMX	 (D-	19)	 (Santa	Cruz	Biotechnology,	Dallas,	 TX,	
USA);	anti-	TP53	mouse	mAb	(BP53-	12)	(Cell	Sciences,	Canton,	MA,	USA);	
mouse	 mAbs	 against	 p21Wafl/Cip1	 (DCS60),	 and	 rabbit	 polyclonal	 Ab	
against	 p53	upregulated	modulator	 of	 apoptosis	 (PUMA)	 (Cell	 Signaling	
Technology,	Danvers,	MA,	USA);	and	rabbit	polyclonal	Ab	against	β- actin 
(Medical	&	Biological	Laboratories,	Nagoya,	Japan).	Both	HRP-	conjugated	
sheep anti- mouse IgG and donkey anti- rabbit IgG sera were purchased 
from	GE	Healthcare	(Chicago,	IL,	USA).	The	HRP-	conjugated	rabbit	anti-	
goat	IgG	was	purchased	from	Sigma-	Aldrich.	Chemiluminescent	detection	
was	carried	out	using	ECL	Select	Western	Blotting	Detection	Reagent	(GE	
Healthcare)	and	the	Ez-	Capture	Imaging	System	(Atto,	Tokyo,	Japan).
2.6 | Quantitative RT- PCR
RNA	samples	were	extracted	from	cell	lysate	using	40	μL	RealTime	
Ready	Cell	Lysis	reagent	(Roche	Diagnostics,	Mannheim,	Germany)	
per well of a 96- well culture plate, according to the manufacturer's 
instructions.	Complementary	DNA	was	synthesized	using	2	μL	RNA	
and 8 μL	Transcriptor	Universal	 cDNA	Master	 (Roche	Diagnostics)	
in 20- μL	 reactions.	 Quantitative	 RT-	PCR	 assays	 were	 carried	 out	
using	 the	 Applied	 Biosystems	 7500	 Fast	 Real-	Time	 PCR	 system	
(Applied	Biosystems,	Foster	City,	CA,	USA)	in	96-	well	plates.	Primer	
and	TaqMan	probe	for	CDKN1A	(p21Cip1)	and	ACTB	(β- actin) were 
obtained	from	Applied	Biosystems	(Assay	ID:	Hs00355782_m1	and	
Hs99999903_m1,	respectively).	Reactions	were	carried	out	in	trip-
licate under standard thermocycling conditions in a 20 μL	 volume	
containing 5 μL	cDNA,	900	nmol/L	primers,	250	nmol/L	probe,	and	
10 μL	TaqMan	Gene	Expression	Master	Mix	 (Applied	Biosystems),	
according to the manufacturer's protocol. The amount of target 
mRNA	was	examined	and	normalized	to	that	of	β- actin.
2.7 | Cell cycle assay
Cells were seeded into 60- mm dishes at 1 × 105/dish.	 After	 over-
night	cultivation,	cells	were	transfected	with	DNA-	modified	siRNAs	
(0.5-	2	nmol/L)	for	24	hours,	then	cultured	in	the	presence	of	5-	FU	
(4 μmol/L).	After	2	days	of	cultivation,	cells	were	gently	 lifted	with	
Accutase	(US	Biotechnologies,	Parker	Ford,	PA,	USA)	at	room	tem-
perature	for	10	minutes.	The	cells	were	then	washed	once	with	PBS	
and	stained	with	a	Cycletest	Plus	DNA	reagent	kit	(BD	Biosciences,	
Franklin	Lakes,	NJ,	USA),	according	to	the	manufacturer's	protocol.	
Flow	cytometry	was	carried	out	using	a	FACSCalibur	flow	cytometer	
and	CellQuest	 software	 (both	BD	Biosciences).	The	percentage	of	
cells	 in	different	 cell	 cycle	phases	was	calculated	using	ModFit	LT	
software	(Verity	Software	House,	Topsham,	ME,	USA).
2.8 | In vivo antitumor effect of 5- FU plus 
knockdown of MDM4 and MDM2
All	 animal	 experiments	 were	 undertaken	 according	 to	 pro-
cedures	 approved	 by	 the	 Institutional	 Animal	 Care	 and	 Use	
Committee of the University of Tsukuba (Tsukuba, Japan). 
Female	 BALB/c	 nude	 mice	 (5	weeks	 old)	 were	 obtained	 from	
Charles River Japan (Kanagawa, Japan) and maintained under 
specific pathogen- free conditions in a temperature and 
humidity- controlled environment. HCT116 cells were sus-
pended in saline solution (Otsuka Pharmaceutical, Tokyo, 
Japan) at a concentration of 5 × 104/μL.	One	hundred	microlit-
ers of the adjusted cell suspension of HCT116 was s.c. injected 
into the right flank of mice under anesthesia. Ten days after 
inoculation, the s.c. xenografted tumors grew to approximately 
50 mm3 in size. The mice were randomly assigned to 4 groups 
(n = 5 per group) as follows: chiCtrl alone (1 mg/kg), mixture of 
chiMDM4 and chiMDM2 (0.5 mg/kg, each), chiCtrl (1 mg/kg) 
plus 5- FU (30 mg/kg), and a mixture of chiMDM4 and chiMDM2 
(0.5	mg/kg,	each)	plus	5-	FU	 (30	mg/kg).	DNA-	modified	siRNA	
was directly injected into tumor once a week (days 0, 7, and 14) 
using	 AteloGene	 as	 described	 in	 the	 manufacturer's	 instruc-
tion. 5- FU was i.p. injected 3 times a week for 3 weeks (days 
1, 4, 6, 8, 11, 13, 15, 18, and 20). Tumor volume was measured 
with a caliper 3 times a week and calculated using a formula 
of V = (length × width2)/2. To monitor health, the mice were 
weighed 3 times a week, and their general physical status was 
recorded daily. Experiments were terminated before the larg-
est size of tumor reached 2000 mm3.
2.9 | Statistical analysis
Statistical significance of differences between various groups was 
evaluated	using	Dunnett's	or	Tukey's	test	(in	vitro	assay).	A	repeated-	
measures	ANOVA	was	used	to	evaluate	the	in	vivo	antitumor	effects	
of	 the	 drugs.	 A	 difference	 between	 the	 experimental	 groups	was	
considered statistically significant at a P-	value	of	<.05.	All	statistical	
analyses were undertaken using SPSS version 25.0 (SPSS, Chicago, 
IL,	USA).
3  | RESULTS
3.1 | Cell growth inhibition of MDM4/MDM2 double 
knockdown and 5- FU in wt TP53 colon and gastric 
cancer cells
To test if double knockdown of MDM4 and MDM2 could enhance the 
antitumor activity of 5- FU in colon and gastric cancers with wtTP53/
highMDM4, the effect of chiMDM4/chiMDM2 on the growth in-
hibitory activity of 5- FU was examined by WST- 8 assay using 2 
colon	cancer	 (HCT116	and	LoVo)	and	2	gastric	cancer	 (SNU-	1	and	
NUGC-	4)	cell	 lines.	As	shown	in	Figure	1A,	a	mixture	of	chiMDM4	
and chiMDM2 in equimolar amounts and 5- FU alone suppressed 
the growth of HCT116 cells in a dose- dependent manner as com-
pared	with	 control	DNA-	modified	 siRNA	 (chiCtrl).	 Combination	 of	
chiMDM4/chiMDM2 and 5- FU suppressed the growth more than 
each alone. Similar enhancement of 5- FU- mediated growth sup-
pression	by	chiMDM4/chiMDM2	was	observed	in	LoVo	(Figure	1B),	
SNU-	1	(Figure	1C),	and	NUGC-	4	cells	(Figure	1D).
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Combination index (CI) values were calculated, and they are sum-
marized in Table 1. The CI value of HCT116 cells was lowest (<0.3), fol-
lowed	by	NUGC-	4	cells	(0.83,	0.77),	LoVo	cells	(0.90,	0.97),	and	SNU-	1	
cells (0.95, 0.97), showing that MDM4/MDM2 double knockdown en-
hanced the antitumor activity of 5- FU synergistically in HCT116 cells 
and	NUGC-	4	cells	and	additively	in	SNU-	1	cells	and	LoVo	cells.
F IGURE  1 Effects of double knockdown of MDM4 and MDM2	and	5-	fluorouracil	(5-	FU)	on	the	growth	of	colon	(HCT116	and	LoVo)	
and	gastric	cancer	cell	lines	(SNU-	1	and	NUGC-	4)	with	wtTP53/high MDM4.	HCT116	(A),	LoVo	(B),	SNU-	1	(C),	and	NUGC-	4	cells	(D)	were	
transfected	with	either	DNA-	modified	control	siRNA	(chiCtrl)	or	mixture	of	DNA-	modified	siRNA	targeting	MDM4 (chiMDM4) and MDM2 
(chiMDM2).	After	4-	16	hours	of	incubation,	cells	were	exposed	to	5-	FU	at	the	indicated	concentrations.	Five	days	after	transfection,	cell	
viability was determined using the WST- 8 assay. Cell viability relative to those transfected with chiCtrl are shown (mean ± SD; n = 3) . *P < 
.05, compared with the chiCtrl
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TABLE  1 Combination index of mixture of chiMDM4/chiMDM2 and 5- fluorouracil (5- FU)
Cell line chiMDM4 (nmol/L) chiMDM2 (nmol/L) 5- FU (4 μmol/L) Combination index
HCT116 0.250 0.250 + 0.28
0.500 0.500 + 0.29
LoVo 0.500 0.500 + 0.90
1.000 1.000 + 0.97
SNU-	1 0.125 0.125 + 0.95
0.250 0.250 + 0.97
NUGC-	4 0.500 0.500 + 0.83
1.000 1.000 + 0.77
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F IGURE  2 Effects of MDM4 knockdown and nutlin- 3 on tumor cell growth and antitumor activity of 5- fluorouracil (5- FU) in colon 
and	gastric	cancer	cells.	A,	Growth	inhibitory	effect	of	MDM4	knockdown	and	nutlin-	3	in	HCT116	(a),	LoVo	(b),	SNU-	1	(c),	and	NUGC-	4	
cells	(d).	Cells	were	transfected	with	either	control	siRNA	(chiCtrl)	or	DNA-	modified	siRNA	targeting	MDM4	(chiMDM4).	After	4-16	hours	
of incubation, cells were exposed to nutlin- 3 at the indicated concentrations. Five days after transfection, cell viability was determined 
using	the	WST-	8	assay.	Cell	viability	relative	to	those	transfected	with	chiCtrl	are	shown	(mean	±	SD;	n	=	3).	B,	Enhancement	of	MDM4 
knockdown/nutlin-	3	on	antitumor	activity	of	5-	FU	in	colon	(HCT116)	and	gastric	cancer	cells	(NUGC-	4).	HCT116	(left)	and	NUGC-	4	cells	
(right)	were	transfected	with	either	chiCtrl	or	chiMDM4.	After	16	hours	of	incubation,	cells	were	exposed	to	nutlin-	3	and	5-	FU	at	the	
indicated concentrations. Five days after transfection, cell viability was determined using the WST- 8 assay. Cell viability relative to those 
transfected with chiCtrl are shown (mean ± SD; n = 3)
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We tested whether nutlin- 3, an inhibitor of MDM2- p53 interac-
tion, could serve as a substitute for chiMDM2 to enhance the anti-
tumor	effect	of	chiMDM4	in	4	cell	lines	(NUGC-	4,	SNU-	1,	HCT116,	
and	LoVo).	As	shown	in	Figure	2A	and	Table	2,	a	synergistic	antitu-
mor effect of chiMDM4 and nutlin- 3 was observed in 3 cell lines 
(NUGC-	4,	HCT116,	and	LoVo),	whereas	a	mostly	additive	effect	was	
seen	in	the	SNU-	1	cell	line.	Next,	we	examined	whether	the	combi-
nation of chiMDM4/nutlin- 3 could enhance the antitumor effect of 
5-	FU	 in	HCT116	and	NUGC-	4	cells	 (Figure	2B,	Table	3).	We	found	
that chiMDM4/nutlin3 synergistically enhanced the 5- FU effect in 
HCT116 (CI, 0.55- 0.93), whereas its effect was additive or even an-
tagonistic	to	5-	FU	in	NUGC-	4	(CI,	0.82-	1.42).
3.2 | Expression of MDM2, MDM4, 
p53, and their downstream molecules by MDM4/
MDM2 double knockdown
To explore the mechanisms by which chiMDM4/chiMDM2 en-
hanced 5- FU- mediated growth suppression in colon and gastric 
cancer cells, expression changes of MDM2, MDM4, p53, p21, and 
PUMA	were	examined	in	2	colon	cancer	(HCT116	and	LoVo)	and	
2	 gastric	 cancer	 cells	 (SNU-	1	 and	 NUGC-	4)	 by	 immunoblotting	
(Figure 3). The results of quantification of immunoblotting bands 
are shown in Table S1.
HCT116 cells are known to have wild and mutant alleles of 
MDM4. The mutant allele contained 1 base deletion of the third 
nucleotide of codon 279 and resulted in frameshift and premature 
termination. This gave rise to a smaller protein of 289 amino acids,32 
which retained a p53- binding region and could exert an inhibitory 
effect toward p53. chiControl- transfected HCT116 cells expressed 
two bands of 80 and 40 kDa (Figure 4), representing wild and mutant 
MDM4, respectively.
chiMDM4/chiMDM2 suppressed both wild and mutant MDM4 
in	 HCT116	 and	 NUGC-	4	 cells	 by	 11-	 and	 10-	fold,	 respectively,	
which	was	more	efficient	than	in	LoVo	(3.8-	fold)	and	SNU-	1	cells	
(1.8- fold). chiMDM4/chiMDM2 also decreased the levels of MDM2 
in all cell lines by 1.3 to 3.7- fold. Knockdown of MDM4/MDM2 con-
comitantly induced the accumulation of p53 and its downstream 
gene	products	of	p21	and	PUMA.	The	enhancing	effects	on	p53	
expression were almost equivalent among the 4 cell lines (2.2 to 
3.0- fold).
5- FU increased p53 and its responsive gene products, MDM2, 
p21,	 and	PUMA	 to	various	degrees	 in	 cell	 lines	 tested	here.	 5-	FU	
accumulated	MDM2	more	 in	NUGC-	4	 (8.8-	fold)	and	HCT116	cells	
(4.2-	fold)	than	in	LoVo	(3.3-	fold)	and	SNU-	1	cells	(1.4-	fold).	 In	con-
trast, the level of MDM4 was inversely related to that of MDM2, 
suggesting that MDM4 might be destabilized by induced MDM2 in 
these cells.
Cell line Nutlin- 3 (μmol/L) chiMDM4 (nmol/L) Combination index
HCT116 1.00 0.50 0.49
2.00 0.50 0.31
5.00 0.50 0.49
1.00 1.00 0.88
2.00 1.00 0.72
5.00 1.00 0.97
LoVo 1.00 1.00 0.48
2.00 1.00 0.35
5.00 1.00 0.30
1.00 2.00 0.51
2.00 2.00 0.33
5.00 2.00 0.28
SNU-	1 1.00 0.25 0.96
2.00 0.25 0.82
5.00 0.25 0.94
1.00 0.50 0.98
2.00 0.50 1.04
5.00 0.50 1.07
NUGC-4 1.00 1.00 0.47
2.00 1.00 0.23
5.00 1.00 0.26
1.00 2.00 0.54
2.00 2.00 0.53
5.00 2.00 0.68
TABLE  2 Combination index of 
chiMDM4 and nutlin- 3
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Treatment with chiMDM4/chiMDM2 plus 5- FU accumulated 
a lower level of MDM2 than 5- FU alone. Furthermore, chiMDM4/
chiMDM2 plus 5- FU most potently suppressed the level of MDM4 
than	either	alone	in	all	tested	cell	lines.	As	a	result,	induction	of	p53	
and p21 was highest in these cells treated with chiMDM4/chiMDM2 
plus 5- FU compared with cells treated with either alone.
Although	both	MDM2	and	p21	were	products	of	p53-	responsive	
genes, 5- FU increased the p21 level less than the MDM2 level in 
HCT116	and	LoVo	cells.	Therefore,	we	analyzed	p21	mRNA	levels	
in HCT116 cells treated with chiMDM4/chiMDM2, 5- FU alone, 
and chiMDM4/chiMDM2 plus 5- FU using quantitative RT- PCR 
(Figure 5). Compared with p21	mRNA	levels	in	chiCtrl-	treated	cells,	
5- FU alone, chiMDM4/chiMDM2 alone, and chiMDM4/chiMDM2 
plus 5- FU increased the level of p21	mRNA	by	2.4-	,	4.1-	,	and	5.1-	fold,	
respectively. These results suggested that p53 activity was highest 
in cells treated with chiMDM4/chiMDM2 plus 5- FU, and p21 might 
be destabilized by increased MDM2 in cells treated with 5- FU.
TABLE  3 Combination index of chiMDM4/nutlin- 3 and 5- fluorouracil (5- FU)
Cell line chiMDM4 (nmol/L) Nutlin- 3 (μmol/L) 5- FU (4 μmol/L) Combination index
HCT116 0.5 2.0 + 0.55
0.5 5.0 + 0.93
1.0 2.0 + 0.48
1.0 5.0 + 0.66
NUGC-	4 1.0 2.0 + 0.82
1.0 5.0 + 1.06
2.0 2.0 + 1.19
2.0 5.0 + 1.42
F IGURE  3 Effects of double knockdown of MDM2 and MDM4 and 5- fluorouracil (5- FU) on levels of p53, p21, and p53 upregulated 
modulator	of	apoptosis	(PUMA)	in	colon	(HCT116	and	LoVo)	and	gastric	cancer	cells	(SNU-	1	and	NUGC-	4).	HCT116,	LoVo,	SNU-	1,	and	
NUGC-	4	cells	were	transfected	with	either	control	siRNA	(chiCtrl)	or	a	mixture	of	DNA-	modified	siRNA	targeting	MDM4 (chiMDM4) and 
MDM2	(chiMDM2).	After	4-	16	hours	of	incubation,	cells	were	exposed	to	5-	FU	at	the	indicated	concentrations.	Twenty-	four	hours	after	
exposure	to	5-	FU,	cells	were	analyzed	for	levels	of	MDM2,	MDM4,	p53,	p21,	and	PUMA	using	immunoblotting.	β- actin was used as an 
internal control
Cell HCT116 LoVo SNU-1 NUGC-4
chiCtrl + – + – + – + – + – + – + – + –
chiMDM4
+
chiMDM2
– + – + – + – + – + – + – + – +
5-FU – – + + – – + + – – + + – – + +
MDM2
MDM4 (80 kDa)
MDM4 (40 kDa)
p53
p21
PUMA
-actin
F IGURE  4 Expression level of MDM4 in wtTP53 colon (HCT116 
and	LoVo)	and	gastric	cancer	cell	lines	(SNU-	1	and	NUGC-	4).	
Expression levels of MDM4 were analyzed by immunoblotting
Cell lines
HC
T1
16
Lo
Vo
SN
U-
1
NU
G
C-
4
80 kDa
40 kDa
MDM4
-actin
MDM4 (80 kDa)/actin 2.5 1.0 1.1 2.1
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3.3 | Cell cycle distribution and apoptosis
Effects of chiMDM4/chiMDM2, 5- FU alone, and chiMDM4/chiMDM2 
plus 5- FU on the cell cycle distribution and apoptosis of colon cancer 
and gastric cancer cells were examined by flow cytometry (Figure 6).
In HCT116 cells, chiMDM4/chiMDM2 increased the fraction 
of the G1 phase and decreased that of the S phase, showing that 
MDM4/MDM2 double knockdown caused G1 arrest. 5- FU decreased 
the G1 phase fraction and increased the S phase fraction, showing 
that 5- FU caused early S phase arrest. The combination of these en-
hanced chiMDM4/chiMDM2- induced G1 arrest, as well as apoptotic 
cell death detected as sub- G1 fraction.
In	 SNU-	1	 cells	 and	LoVo	cells,	 chiMDM4/chiMDM2	caused	G1 
arrest. 5- FU alone caused weak G1	arrest	 in	LoVo	cells	but	had	an	
undetectable	 effect	 on	 the	 cell	 cycle	 distribution	 in	 SNU-	1	 cells.	
Simultaneous treatment with chiMDM4/chiMDM2 and 5- FU alone 
enhanced G1 arrest. chiMDM4/chiMDM2 plus 5- FU increased the 
population	of	apoptotic	cells	in	SNU-	1	cells	but	not	in	LoVo	cells.
In	NUGC-	4	cells,	5-	FU	alone	as	well	as	chiMDM4/chiMDM2	in-
duced G1 arrest but not apoptosis. 5-FU and chiMDM4/chiMDM2 
decreased the S phase fraction, whereas a combination of these 
two had a faint change in the S phase fraction. Furthermore, a 
small increase in the G1 phase fraction was observed with a com-
bination of 5- FU and chiMDM2/chiMDM4 (5- FU alone, 77%; 
chiMDM2/chiMDM4 alone, 76%; 5- FU plus chiMDM4/chiMDM2, 
80%), suggesting that chiMDM4/chiMDM2 marginally enhanced 
5- FU- induced G1 arrest.
3.4 | In vivo antitumor activity
To test whether chiMDM4/chiMDM2 could inhibit in vivo tumor 
growth and enhance the antitumor activity of 5- FU, we examined 
the effects of chiCtrl, chiCtrl plus 5- FU, chiMDM4/chiMDM2, and 
chiMDM4/chiMDM2 plus 5- FU on the growth of HCT116 xenograft 
tumors in mice. chiMDM4/chiMDM2 alone and chiCtrl plus 5- FU 
slowed the tumor growth rate compared with chiCtrl alone (Figure 7), 
showing that double knockdown suppressed in vivo tumor growth of 
wtTP53/highMDM4 colon cancer. 5- FU plus chiMDM4/chiMDM2 
most potently inhibited the tumor growth compared with chiCtrl/5-
 FU and chiMDM4/chiMDM2.
4  | DISCUSSION
5- FU is widely used for chemotherapy in various cancers includ-
ing colon, stomach, and breast cancer. In our previous study, si-
multaneous knockdown of MDM4 and MDM2 using synthetic 
DNA-	substituted	siRNAs	 (chiMDM4	and	chiMDM2)	was	shown	to	
synergistically suppress the growth of cancer cells with wtTP53/
highMDM4.16 In this study, we showed that double knockdown of 
MDM4 and MDM2 enhanced the antitumor activity of 5- FU in colon 
and gastric cancer cells with wtTP53/highMDM4.
In all cell lines used in this study, 5- FU induces p53 expression 
and	concomitant	MDM2.	Accumulated	MDM2,	functioning	as	a	neg-
ative feedback regulator, can compromise p53- mediated antitumor 
activity in 5- FU- treated cancer cells. In HCT116 cells, 5- FU increased 
p21	mRNA	and	MDM2	but	failed	to	accumulate	p21,	suggesting	that	
MDM2 might antagonize p53- mediated growth inhibition through 
ubiquitination and destabilization of p21.33 In this context, MDM2 
knockdown using chiMDM4/chiMDM2 might disrupt these negative 
effects of MDM2 on p53- and p21- mediated growth inhibition and 
potentiate the antitumor activity of 5- FU.
We revealed that chiMDM4- mediated growth inhibition 
could be synergistically enhanced by nutlin- 3, as was observed by 
chiMDM2.34 However, enhancement of 5- FU antitumor activity 
by chiMDM4/nutlin- 3 was less efficient than that by chiMDM4/
chiMDM2.	 Particularly	 in	 NUGC-	4	 cells,	 chiMDM4/nutlin-	3	 was	
even antagonistic to 5- FU at high concentrations. 5-FU caused 
F IGURE  5 Effects of double 
knockdown of MDM4 and MDM2 and 
5- fluorouracil (5- FU) on the level of 
p21	mRNA	in	HCT116	cells.	HCT116	
cells were transfected with either 
control	siRNA	(chiCtrl)	or	a	mixture	of	
DNA-	modified	siRNA	targeting	MDM4 
(chiMDM4) and MDM2 (chiMDM2) 
for 16 hours and then cultured in the 
presence of 5- FU. Forty- eight hours after 
transfection, the cells were analyzed for 
their p21	mRNA	level	using	quantitative	
RT- PCR. p21	mRNA	levels	relative	to	
those transfected with chiCtrl are shown. 
*P < .05, compared with the chiCtrl
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MDM2	 accumulation	 in	 NUGC-	4	 more	 intensely	 than	 in	 HCT116	
cells.	 Addition	 of	 nutlin-	3	 to	 5-	FU-	exposed	 cells	 may	 further	 the	
increase MDM2 level, which partially inactivates negative growth 
signals	by	direct	interactions	with	p53,	p21,	RB,	and	E2F1	in	these	
cells.33,35 Small molecules and peptides targeting MDM2 and MDM4 
have been developed,18 most of which disrupt MDM2- p53 interac-
tions and increase MDM2 expression, similar to nutlin- 3.13,36 Thus, 
MDM2 knockdown might have some advantages over MDM2- p53 
inhibitors in the treatment of cancers carrying wtTP53.
The magnitude of enhancement of chiMDM4/chiMDM2 on 
5- FU- mediated antitumor activity appears to be related to the mag-
nitude of MDM4 suppression. 5-FU suppresses MDM4 in synergistic 
responders	 (HCT116	and	NUGC-	4)	more	 strongly	 than	 in	 additive	
responders	 (SNU-	1	 and	 LoVo).	 It	 remains	 unknown	how	5-	FU	de-
creases MDM4 levels in these cells. 5-FU might destabilize MDM4 
through the increase of MDM2 induced by p53 activation because 
MDM2 can ubiquitinate and destabilize MDM4.37 Furthermore, 
MDM4 knockdown by chiMDM4/chMDM2 is more efficient in 
synergistic	 responders	 (HCT116	 and	 NUGC-	4)	 than	 additive	 re-
sponders	(LoVo	and	SNU-	1).	The	expression	level	of	MDM4	differs	
among cell lines (Figure 4). Synergistic responders (HCT116 and 
NUGC-	4)	express	higher	levels	of	MDM4	than	additive	responders	
(SNU-	1	and	LoVo).	Synergistic	responders	could	be	more	dependent	
on MDM4 expression for their growth and survival than additive 
F IGURE  6 Effects of double 
knockdown of MDM4 and MDM2 and 
5- fluorouracil (5- FU) on cell cycle 
distribution	of	colon	(HCT116	and	LoVo)	
and	gastric	cancer	cells	(SNU-	1	and	
NUGC-	4).	HCT116	(top	left),	LoVo	(top	
right),	SNU-	1	(bottom	left),	and	NUGC-	4	
cells (bottom right) were transfected with 
control	siRNA	(chiCtrl)	or	a	mixture	of	
DNA-	modified	siRNA	targeting	MDM4 
(chiMDM4) and MDM2 (chiMDM2) 
overnight,	then	exposed	to	5-	FU.	After	
overnight cultivation, the cells were 
analyzed for cell cycle distribution by flow 
cytometry
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responders.38,39	 Knockdown	 efficiency	 of	 synthetic	 siRNA	 might	
depend on various factors, including transfection efficiencies of 
siRNA	and	RNA-	induced	silencing	complex	formation.	RNA-	induced	
silencing complex formation could be determined by the abundance 
of	AGO2	protein,	Hsc70/Hsp90	chaperone,	 and	endoribonuclease	
complex, consisting of Trax and Translin.40 Factors regulating MDM4 
knockdown efficiency are now being analyzed.
This study shows that 5- FU causes similar p53 accumulation in 
all colon and gastric cancer cell lines carrying wtTP53/highMDM4. 
However, the effect of 5- FU on the cell cycle distribution differs 
among them: 5- FU causes cell cycle arrest in the early S phase 
in HCT116 cells, whereas it induces G1	 arrest	 in	 LoVo	 cells	 and	
NUGC-	4	 cells.	 5-FU	 has	 two	 independent	 mechanisms	 of	 ac-
tion.41-43	It	blocks	DNA	replication	by	inhibiting	thymidine	synthe-
sis, resulting in cell cycle arrest in the early S phase. It also causes 
nucleolar	 stress	 by	 being	 incorporated	 into	 ribosomal	 RNA	 and	
interfering	 in	 subsequent	 ribosomal	 RNA	 processing.	 This	 leads	
to p53 activation, which induces G1 arrest and apoptosis. 5- FU 
might	activate	p53	more	potently	 in	LoVo	and	NUGC-	4	cells	than	
in	HCT116	cells.	Although	 inhibition	of	DNA	replication	has	been	
reported as the major mechanism of action of 5- FU in most can-
cer cells, the magnitude of nucleolar stress could vary among cell 
lines, dependent on the efficiency of fluorouridine incorporation 
into	ribosomal	RNA.	Although	5-	FU	causes	early	S-	phase	arrest	in	
HCT116 cells, its combination with chiMDM4/chiMDM2 dramati-
cally shifts the effect on cell cycle distribution from early S- phase 
arrest to G1 arrest with strong p53 activation. This result suggests 
that the addition of chiMDM4/chiMDM2 might change the main 
action	mechanism	 of	 5-	FU	 from	 inhibition	 of	 DNA	 replication	 to	
augmented activation of p53.
chiMDM4/chiMDM2 plus 5- FU induced larger populations of 
apoptotic	cells	in	SNU-	1	cells	than	in	LoVo	cells.	Activated	p53	can	
trigger apoptosis by modulating the expression of genes involved in 
intrinsic (eg, PUMA, BAX, and BCL2) and extrinsic apoptosis path-
ways	(FAS-	L	and	FAS).44 Inducibility of p53- mediated apoptosis de-
pends on the expression and structures of these genes in individual 
cell	 lines.	LoVo	cells	but	not	SNU-	1	cells	carry	BAX mutations,45,46 
which could be one of the mechanisms by which some cancer cells 
acquire resistance to p53- triggered apoptosis.
In the present study, we show that MDM4/MDM2 double 
knockdown inhibits in vivo tumor growth and enhances the anti-
tumor effect of 5- FU without any intolerable toxicity. Recent ad-
vances in the delivery system for oligonucleotides47 could enable 
chiMDM4/chiMDM2 to be applied to the treatment of wtTP53/
highMDM4	 tumors.	 Approximately	 50%	 of	 human	 cancers	 ex-
press wtTP53,48 in some fraction of which wtTP53 is directly sup-
pressed by MDM2 alone or MDM2 combined with MDM4. Thus, 
MDM2 and MDM4 are ideal targets of therapy for these tumors. 
In addition, MDM2 knockout was shown to suppress the growth 
of tumors lacking TP53 alleles by inducing p53- responsive gene 
through TP73- mediated transactivation.49 MDM4/MDM2 knock-
down can be potentially used for the treatment of cancers lacking 
p53 expression.
In conclusion, the double knockdown of MDM4 and MDM2 
enhances in vitro and in vivo antitumor activity of 5- FU toward 
gastrointestinal cancer with wtTP53/highMDM4. Combination 
of	 siRNAs	 targeting	MDM4 and MDM2 and cytotoxic anticancer 
drugs including 5- FU could be a novel therapeutic strategy for 
such cancers.
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